Iovance down 18% warning it could be impacted by geopolitical instability, inflation
Although it reported 2024 Q4 and full-year results that beat expectations and reiterated 2025 guidance that includes consensus figures, Iovance Biotherapeutics (NASDAQ:IOVA) has plunged ~18% after ...
pharmaphorum6d
Novartis reports two liver-related deaths with Zolgensma
Novartis said it was updating the labelling ... The two deaths occurred in children in Russia and Kazakhstan, with the liver failure starting five to six weeks after administration of the adeno ...